Patents by Inventor Maurice R. Hilleman

Maurice R. Hilleman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cell culture of hepatitis A virus
    Patent number: 5766603
    Abstract: Hepatitis A virus is attenuated in virulence by in vitro passage in susceptible cell cultures, without prior passage in a subhuman primate. This process results in a live, attenuated hepatitis A virus vaccine suitable for human disease prevention.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 16, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Paula A. Giesa, Philip J. Provost, Maurice R. Hilleman
  • Cell culture of hepatitis A virus
    Patent number: 5514376
    Abstract: Hepatitis A virus is attenuated in virulence by in vitro passage in susceptible cell cultures, without prior passage in a subhuman primate. This process results in a live, attenuated hepatitis A virus vaccine suitable for human disease prevention.
    Type: Grant
    Filed: February 10, 1993
    Date of Patent: May 7, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Paula A. Giesa, Philip J. Provost, Maurice R. Hilleman
  • Attenuated hepatitis A virus
    Patent number: 5021348
    Abstract: Hepatitis A virus is attenuated by propagation in cell culture in vitro by direct inoculation of the cell cultures with a human clinical specimen containing the virus.
    Type: Grant
    Filed: May 14, 1984
    Date of Patent: June 4, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Paula A. Giesa, Maurice R. Hilleman, Philip J. Provost
  • Coupled H. influenzae type B vaccine
    Patent number: 4459286
    Abstract: Haemophilus influenzae type B polysaccharide is coupled through a spacer to a serotype outer membrane protein from Neisseria meningitidis. This conjugate has enhanced antigenicity and immunogenicity relative to the unconjugated polysaccharide.
    Type: Grant
    Filed: January 31, 1983
    Date of Patent: July 10, 1984
    Assignee: Merck & Co., Inc.
    Inventors: Maurice R. Hilleman, Joseph Y. Tai, Richard L. Tolman, Philip P. Vella
  • Parainfluenza virus vaccine and its preparation
    Patent number: 4215107
    Abstract: By serially passaging virulent parainfluenza virus in tissue culture prepared from embryonated hens' eggs or human diploid lung fibroblasts, a live, non-pathogenic but antigenic live parainfluenza virus is produced. This virus is useful in preparing a live virus vaccine.
    Type: Grant
    Filed: December 29, 1978
    Date of Patent: July 29, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Eugene B. Buynak, Maurice R. Hilleman
  • Hepatitis a virus cell culture in vitro
    Patent number: 4164566
    Abstract: Hepatitis A virus is passaged at least once in a susceptible sub-human primate; the infected liver from such passage is used to inoculate an in vitro cell culture, the inoculated cell culture is incubated until hepatitis A antigen is detected in the cell sheet or culture fluid, and at least two serial in vitro passages in cell culture are carried out. The hepatitis A virus so modified can be used to prepare live, attenuated hepatitis A vaccine or an inactivated hepatitis A vaccine.
    Type: Grant
    Filed: August 17, 1978
    Date of Patent: August 14, 1979
    Assignee: Merck & Co., Inc.
    Inventors: Philip J. Provost, Maurice R. Hilleman
  • Respiratory syncytial vaccine
    Patent number: 4145252
    Abstract: By serially passaging virulent respiratory syncytial virus in human diploid lung fibroblasts, a non-pathogenic but antigenic live respiratory syncytial virus is produced. This virus is useful in preparing a live virus vaccine.
    Type: Grant
    Filed: June 26, 1978
    Date of Patent: March 20, 1979
    Assignee: Merck & Co., Inc.
    Inventors: Eugene B. Buynak, Maurice R. Hilleman
  • Polynucleotides active as inducers of interferon production in living animal cells
    Patent number: 4124702
    Abstract: Polynucleotides which are multistranded are active as inducers of interferon production in living animal cells. They may be:A. Synthetically complexed polymers of two homopolynucleotides.B. A nucleic acid released by phenol from a ribonucleic acid complex elaborated by the growth of Penicillium funiculosum.C. A ribonucleic acid from reovirus type 3 virions.D. Replicative forms of nucleic acids.
    Type: Grant
    Filed: December 14, 1976
    Date of Patent: November 7, 1978
    Assignee: Merck & Co., Inc.
    Inventors: George P. Lampson, Alfred A. Tytell, Arthur K. Field, Maurice R. Hilleman
  • Respiratory synctial vaccine
    Patent number: 4122167
    Abstract: By serially passaging virulent respiratory syncytial virus in human diploid lung fibroblasts, a non-pathogenic but antigenic live respiratory syncytial virus is produced. This virus is useful in preparing a live virus vaccine.
    Type: Grant
    Filed: August 17, 1977
    Date of Patent: October 24, 1978
    Assignee: Merck & Co., Inc.
    Inventors: Eugene B. Buynak, Maurice R. Hilleman
  • Water-in-oil adjuvant composition
    Patent number: 4069313
    Abstract: Pure isomannide monooleate and pure aluminum monostearate are used singularly or in combination in the preparation of emulsion type adjuvant vaccines to yield an adjuvant superior to prior art adjuvants which employ commercial mannide monooleate and aluminum monostearate. Highly desirable formulations are obtained by the inclusion of pure aluminum monostearate as a stabilizer in combination with the pure isomannide monooleate.
    Type: Grant
    Filed: April 7, 1976
    Date of Patent: January 17, 1978
    Assignee: Merck & Co., Inc.
    Inventors: Allen F. Woodhour, Maurice R. Hilleman
  • Hepatitis A antigen
    Patent number: 4031203
    Abstract: Hepatitis A antigen obtained from the livers of non-human primates infected with hepatitis A (infectious hepatitis) virus has been found to be usable in fast, simple assays for hepatitis A antibody and thus usable in diagnosis of hepatitis A disease in humans, and for the preparation of hepatitis A vaccine.
    Type: Grant
    Filed: June 7, 1976
    Date of Patent: June 21, 1977
    Assignee: Merck & Co., Inc.
    Inventors: Philip J. Provost, Oswald L. Ittensohn, Maurice R. Hilleman
  • Hepatitis A antigen
    Patent number: 4029764
    Abstract: Hepatitis A antigen obtained from the livers of non-human primates infected with hepatitis A (infectious hepatitis) virus has been found to be usable in fast, simple assays for hepatitis A antibody and thus usable in diagnosis of hepatitis A disease in humans, and for the preparation of hepatitis A vaccine.
    Type: Grant
    Filed: December 9, 1974
    Date of Patent: June 14, 1977
    Assignee: Merck & Co., Inc.
    Inventors: Philip J. Provost, Oswald L. Ittensohn, Maurice R. Hilleman
  • Vaccine delivery system
    Patent number: 4022206
    Abstract: Vaccine delivery system having a lyophilized vaccine in human dosage concentration loaded into presterilized single dosage syringe having a squeezable body portion and a separate package containing enough water for injection to reconstitute the single dose of lyophilized vaccine.
    Type: Grant
    Filed: August 1, 1975
    Date of Patent: May 10, 1977
    Assignee: Merck & Co., Inc.
    Inventors: Maurice R. Hilleman, William J. McAleer
  • Syringe containing frozen vaccine
    Patent number: 4018222
    Abstract: Vaccine delivery system wherein an aqueous vaccine diluted to human dosage concentration is loaded into presterilized single dosage syringes having a squeezable body portion and wherein a plurality of these syringes are sealed inside a bag and the contents of the syringes are frozen to preserve the titer of the vaccine.
    Type: Grant
    Filed: May 13, 1975
    Date of Patent: April 19, 1977
    Assignee: Merck & Co., Inc.
    Inventors: William J. McAleer, Maurice R. Hilleman
  • Hepatitis A antigen
    Patent number: 4017601
    Abstract: Hepatitis A antigen obtained from the stools of patients infected with hepatitis A (infectious hepatitis) virus has been found to be usable in fast, simple assays for hepatitis A antibody and thus usable in diagnosis of hepatitis A disease, and for the preparation of hepatitis A vaccine.
    Type: Grant
    Filed: October 16, 1975
    Date of Patent: April 12, 1977
    Assignee: Merck & Co., Inc.
    Inventors: Maurice R. Hilleman, William J. Miller, Philip J. Provost
  • Cell removing device
    Patent number: 4004981
    Abstract: Apparatus for physically removing cells in sterile manner from a disc stack on which the cells have been cultured comprises a substantially shaft-like member having at least one rod-like member mounted at substantially a right angle to the axis of the shaft.
    Type: Grant
    Filed: May 1, 1975
    Date of Patent: January 25, 1977
    Assignee: Merck & Co., Inc.
    Inventors: William M. Hurni, William J. McAleer, Maurice R. Hilleman
  • Varicella vaccine and process for its preparation
    Patent number: 4000256
    Abstract: Preparation of safe, live, attenuated varicella virus vaccine by serial propagation of varicella virus in tissue cell culture systems.
    Type: Grant
    Filed: July 2, 1975
    Date of Patent: December 28, 1976
    Assignee: Merck & Co., Inc.
    Inventors: Maurice R. Hilleman, Eugene B. Buynak, Beverly J. Neff
  • Water-in-oil adjuvant composition
    Patent number: 3983228
    Abstract: Pure isomannide monooleate and pure aluminum monostearate are used singularly or in combination in the preparation of emulsion type adjuvant vaccines to yield an adjuvant superior to prior art adjuvants which employ commercial mannide monooleate and aluminum monostearate. Highly desirable formulations are obtained by the inclusion of pure aluminum monostearate as a stabilizer in combination with the pure isomannide monooleate.
    Type: Grant
    Filed: November 19, 1974
    Date of Patent: September 28, 1976
    Assignee: Merck & Co., Inc.
    Inventors: Allen F. Woodhour, Maurice R. Hilleman